Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

AST-induced bone loss in men with prostate cancer: exercise as a potential countermeasure.

Bolam KA, Galvão DA, Spry N, Newton RU, Taaffe DR.

Prostate Cancer Prostatic Dis. 2012 Dec;15(4):329-38. doi: 10.1038/pcan.2012.22. Epub 2012 Jun 26. Review.

PMID:
22733158
2.

Background to and management of treatment-related bone loss in prostate cancer.

Berruti A, Tucci M, Terrone C, Gorzegno G, Scarpa RM, Angeli A, Dogliotti L.

Drugs Aging. 2002;19(12):899-910. Review.

PMID:
12495366
3.

A pilot study of exercise in men with prostate cancer receiving androgen deprivation therapy.

Lee CE, Leslie WD, Lau YK.

BMC Cancer. 2012 Mar 21;12:103. doi: 10.1186/1471-2407-12-103.

4.
5.

Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial.

Galvão DA, Taaffe DR, Spry N, Joseph D, Newton RU.

J Clin Oncol. 2010 Jan 10;28(2):340-7. doi: 10.1200/JCO.2009.23.2488. Epub 2009 Nov 30.

6.

The role of bisphosphonates in men with prostate cancer receiving androgen deprivation therapy.

Smith MR.

Oncology (Williston Park). 2004 May;18(5 Suppl 3):21-5. Review.

PMID:
15202584
7.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
9.

Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy.

Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD.

Med J Aust. 2011 Mar 21;194(6):301-6. Review.

PMID:
21426285
10.

Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.

Ross RW, Small EJ.

J Urol. 2002 May;167(5):1952-6. Review.

PMID:
11956415
11.

Exercise can prevent and even reverse adverse effects of androgen suppression treatment in men with prostate cancer.

Galvão DA, Taaffe DR, Spry N, Newton RU.

Prostate Cancer Prostatic Dis. 2007;10(4):340-6. Epub 2007 May 8. Review.

PMID:
17486110
12.

Prostate cancer, osteoporosis and fracture risk.

Allain TJ.

Gerontology. 2006;52(2):107-10. Review.

PMID:
16508318
13.

Cancer treatment-induced bone loss in breast and prostate cancer.

Saad F, Adachi JD, Brown JP, Canning LA, Gelmon KA, Josse RG, Pritchard KI.

J Clin Oncol. 2008 Nov 20;26(33):5465-76. doi: 10.1200/JCO.2008.18.4184. Epub 2008 Oct 27. Review.

PMID:
18955443
14.

Can exercise ameliorate treatment toxicity during the initial phase of testosterone deprivation in prostate cancer patients? Is this more effective than delayed rehabilitation?

Newton RU, Taaffe DR, Spry N, Cormie P, Chambers SK, Gardiner RA, Shum DH, Joseph D, Galvão DA.

BMC Cancer. 2012 Sep 26;12:432. doi: 10.1186/1471-2407-12-432.

15.

Osteoporosis during androgen deprivation therapy for prostate cancer.

Smith MR.

Urology. 2002 Sep;60(3 Suppl 1):79-85; discussion 86. Review.

PMID:
12231056
16.
17.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

18.

Osteoporosis due to androgen deprivation therapy in men with prostate cancer.

Daniell HW.

Urology. 2001 Aug;58(2 Suppl 1):101-7. Review.

PMID:
11502461
19.

Nursing implications of androgen deprivation therapy-associated bone loss.

Weingard KK.

Urol Nurs. 2006 Aug;26(4):261-9; quiz 270. Review.

PMID:
16939043
20.

Management of bone loss in men with prostate cancer.

Higano CS.

J Urol. 2003 Dec;170(6 Pt 2):S59-63; discussion S64. Review.

PMID:
14610412
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk